Hellenic journal of nuclear medicine最新文献

{"title":"Analysis of outcome in patients with different primary localisation of neuroendocrine tumors after PRRT. 10 years single institution experience.","authors":"Filip Veličković, Marina Vlajković, Đuro Macut, Miloš Stević","doi":"10.1967/s002449913003","DOIUrl":"10.1967/s002449913003","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this retrospective study is to analyze the outcome and survival of patients with well-differentiated metastatic neuroendocrine neoplasm (NEN) treated with peptide receptor radionuclide therapy (PRRT).</p><p><strong>Subjects and methods: </strong>The treatment was applied to 32 subjects, 18 men and 14 women, aged 39-79 years (median 65 years). The dominant grade of the tumor according to the Ki-67 index was G2 (75%) compared to G1 (25%). The average number of three-day protocol PRRT cycles was 4 (1.00-9.00). Lutetium-177- DOTA⁰,Tyr³,Thr⁸-octreotide (¹⁷⁷Lu-DOTA-TATE) was used in 22 (69%), both ¹⁷⁷Lu-DOTA-TATE and yttrium-90-DOTA⁰,Tyr³-octreotide (⁹⁰Y-DOTA-TOC) in 8 (25%), and ⁹⁰Y-DOTA-TOC in 2 (6%) patients. No adverse effects of PRRT were recorded excerpt one patient who has died soon after the first therapy due to ileus after surgery.</p><p><strong>Results: </strong>Response to PRRT according to response evaluation criteria in solid tumors (RECIST) 1.1. criteria showed that 9 (28%) patients had disease progression, 16 (50%) had stable disease, and 7 (22%) had partial remission. Significantly shorter time until progression or death of 18 months was detected for patients with disease progression than for other groups with stable disease (34.5 months, P<0.02) and partial remission (35 months, P<0.05). However, the values obtained for overall survival were not significantly different between the studied groups being 33 months in subjects with disease progression, and 34.5 and 35 months in groups with stable disease and partial remission, respectively. In 6 subjects, an asymptomatic low hemoglobin level was detected that did not require intervention (Grade1). In 2 subjects, nephrotoxicity occurred with glomerular filtration rate (GFR) values below 30mL/min/1.73m² (Grade3).</p><p><strong>Conclusion: </strong>It can be concluded that PRRT according to a three-day nephroprotection protocol is a reliable and safe method of treatment for advanced NEN. Longer time to disease progression and overall survival in most patients underline the great potential of this treatment method in patients with advanced NEN.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"85-93"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking-associated inflammation: A dual ¹⁸F-FDG PET/CT analysis of tonsillar and aortic inflammation using liver-normalized SUVmax.","authors":"Emmanouil Panagiotidis, George Angelidis, Anna Paschali, Theodoros Kalathas, Varvara Valotassiou, Vasiliki Chatzipavlidou, Panagiotis Georgoulias","doi":"10.1967/s002449913000","DOIUrl":"10.1967/s002449913000","url":null,"abstract":"<p><strong>Objective: </strong>Cigarette smoking alters immune and vascular systems, yet its dual inflammatory impact on mucosal lymphoid tissues and arterial walls remains underexplored in vivo. This study employs fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) with liver-normalized maximum standardized uptake value (SUVmax) to assess metabolic inflammation in Waldeyer's ring and the thoracic aorta across smoking groups.</p><p><strong>Subjects and methods: </strong>We retrospectively analyzed ¹⁸F-FDG PET/CT scans from 222 patients categorized by smoking status. Maximum SUV was recorded in the palatine, lingual, and nasopharyngeal tonsils and the thoracic aorta. Values were normalized to liver uptake. Group differences were analyzed using Kruskal-Wallis tests with Bonferroni-corrected Mann-Whitney post hoc comparisons. Pearson correlation assessed associations with cigarette consumption.</p><p><strong>Results: </strong>Smokers had slightly reduced tonsillar SUVmax values, especially in the lingual tonsil (mean 3.56 vs. 3.82 in non-smokers), but these differences were not statistically significant after liver normalization. In contrast, raw aortic SUVmax was highest in non-smokers (2.72), but after normalization, ex-smokers demonstrated significantly elevated aortic uptake (P=0.016). No significant associations were observed between cigarette quantity and regional SUV values, possibly due to individual variability and confounding metabolic factors such as body mass index (BMI).</p><p><strong>Conclusion: </strong>Fluorine-18-FDG PET/CT reveals mild immune suppression in tonsillar lymphoid tissue among smokers and persistent vascular inflammation in ex-smokers. Liver normalization is essential for identifying true inflammatory differences in metabolically heterogeneous populations. These findings suggest that inflammation is a multiparametric process influenced by factors such as BMI and metabolic status, which may mask smoking-related effects unless properly adjusted for.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"64-69"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atlantoaxial joint involvement in rheumatoid arthritis: Insights from ¹⁸F-NaF and ¹⁸F-FDG PET.","authors":"Lancelot Herpin, Shinya Yamaguchi, Shizuka Yamamoto, Robert Subtirelu, Shiv Patil, Thomas Werner, Joshua Baker, Mona Elisabeth Revheim, Abass Alavi","doi":"10.1967/s002449913011","DOIUrl":"10.1967/s002449913011","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is a leading cause of cervical spine morbidity and neurological dysfunction. Atlantoaxial joint involvement is frequently observed on computed tomography (CT) or magnetic resonance imaging (MRI), yet structural imaging alone cannot visualize inflammatory or osteogenic changes characteristic of active disease. Fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/CT enables the in-vivo assessment of glucose metabolism while ¹⁸F-sodium fluoride (¹⁸F-NaF) reflects osseous metabolism. In combination, these tracers offer complementary insights that may facilitate detection of RA-related pathophysiology. In this report, we present active bone turnover of the atlantoaxial joint without evidence of inflammation identified on PET/CT in a 59-year-old woman with RA.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"135-136"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extensive melorheostosis of the upper extremity: Evaluation of disease activity with ^99mTc-MDP bone scintigraphy.","authors":"Juncen Guo, Qiuping Fan","doi":"10.1967/s002449913009","DOIUrl":"10.1967/s002449913009","url":null,"abstract":"<p><p>Melorheostosis is a rare, sporadic sclerosing bone dysplasia characterized by a \"dripping candle wax\" appearance on imaging. We report a case of a 29-year-old male with a 20-year progressive history of bone overgrowth and joint contracture in the left upper extremity. Technetium-99m-methylenediphosphonate (^99mTc-MDP) bone scintigraphy demonstrated intense tracer uptake, indicating high metabolic activity despite the long-term disease course. Three-dimensional computed tomography (CT) reconstruction visualized extensive hyperostosis crossing multiple joints, while magnetic resonance imaging (MRI) revealed associated soft tissue involvement. The diagnosis was confirmed by biopsy. This case highlights the value of multimodality imaging in assessing the extent and activity of this rare condition to guide surgical intervention.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"129-131"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of the heterogeneity index in assessing treatment response using ¹⁸F-FDG PET/CT in locally advanced and advanced lung cancers.","authors":"Yiğithan Okar, Burcu Esen Akkaş, Reyhan Toyran, Muammer Urhan","doi":"10.1967/s002449913004","DOIUrl":"10.1967/s002449913004","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Intratumoral metabolic heterogeneity may influence treatment response in lung cancer, and the heterogeneity index (HI), derived from threshold-based metabolic tumor volume (MTV) measurements, has been proposed as a simple fluorine-18-fluorodeoxyglucose (&lt;sup&gt;18&lt;/sup&gt;F-FDG) positron emission tomography/computed tomography (PET/CT)-based parameter to estimate this variability. This retrospective single-center study evaluated the predictive value of HI for treatment response in patients with locally advanced and advanced lung cancer undergoing chemoradiotherapy and compared its performance with conventional PET-derived volumetric parameters.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Subjects and methods: &lt;/strong&gt;Forty-four patients with stage III-IV lung cancer who underwent pretreatment &lt;sup&gt;18&lt;/sup&gt;F-FDG PET/CT followed by chemoradiotherapy were retrospectively analyzed. PET-derived parameters, including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), MTV, total lesion glycolysis (TLG), and HI, were calculated from baseline scans. HI was derived from the slope of linear regression using MTV values measured at multiple threshold levels. Treatment response was classified as regression or progression based on follow-up imaging according to positron emission tomography response criteria in solid tumors (PERCIST). Receiver operating characteristic (ROC) analysis was used to evaluate the predictive performance of MTV and HI, and multivariate logistic regression was performed to identify independent predictors of disease progression.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of the 44 patients, 19 (43.2%) showed regression and 25 (56.8%) showed progression. Metabolic tumor volume and HI were significantly higher in patients with progression (P=0.047 and P=0.040, respectively). Receiver operating characteristic analysis demonstrated modest discriminative performance for MTV (area under the curve [AUC]: 0.677; 95% confidence interval [CI]: 0.519-0.810) and HI (AUC: 0.682; 95% CI: 0.525-0.814), with high sensitivity but low specificity for both parameters. Heterogeneity index showed an extremely strong correlation with MTV (r=0.997), indicating substantial overlap between the two measures. In multivariate analysis, only advanced tumor stage (T3-T4) remained an independent predictor of progression (odds ratio [OR]: 6.801; 95% CI: 1.271-36.398; P=0.025), whereas HI did not retain independent significance.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;These findings indicate that HI has limited but statistically significant predictive value for treatment response in locally advanced and advanced lung cancer and performs similarly to MTV. Given its extreme collinearity with MTV, HI should be interpreted primarily as a derivative parameter reflecting tumor burden rather than as an independent heterogeneity biomarker. Nevertheless, because of its simple calculation and broad availability, HI may serve as a practical adjunct metabolic paramete","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"94-103"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of radioactive iodine therapy with fixed-activity regimen in pediatric Graves' disease.","authors":"Yutapong Raruenrom, Pattara Wiromrat","doi":"10.1967/s002449913005","DOIUrl":"10.1967/s002449913005","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the success rates of radioactive iodine therapy (RAIT) with fixed activity of 10mCi and 15mCi in pediatric patients with Graves' disease (GD).</p><p><strong>Subjects and methods: </strong>This retrospective study included patients aged ≤18 years diagnosed with GD who received 1^st dose of RAIT by fixed activity regimen, either 10mCi or 15mCi. The rates of successful therapy, defined as the induction of hypothyroidism within six months after RAIT, were compared between the two RAIT dosage groups. We also evaluated factors associated with the successful RAIT and median duration for achieving hypothyroidism between the two groups.</p><p><strong>Results: </strong>Eighty-seven patients (86.2% females, mean (±standard deviation [SD]) age 14.7±2.5 years, 44.8% received 10mCi radioiodine) were included in the analysis. Patients who received 10mCi radioiodine exhibited a younger age at the GD diagnosis (P=0.038), younger age at the RAIT (P<0.001), and smaller thyroid size (P<0.001). The success rates of 10- vs 15mCi radioiodine were not significantly different (76.9% vs 64.6%, P=0.211). There was also no significant difference in the median duration to achieve hypothyroidism in 10- vs 15mCi groups (4.6 vs 5.1 months, P=0.306). Discontinuation of antithyroid drug (ATD) for more than three days prior to RAIT was the only independent factor for successful RAIT (adjusted odds ratio [OR] 3.67, P=0.015).</p><p><strong>Conclusion: </strong>Radioactive iodine therapy with fixed-activity regimen showed high success rates in pediatric patients with GD. Antithyroid drug withdrawal for more than three days prior to RAIT was recommended for the optimal therapeutic outcomes.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"104-108"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary hypertrophic osteoarthropathy with anemia as assessed by ¹⁸F-FDG PET/CT.","authors":"Daoying Wang, Zhiming Wang, Haiyang Li","doi":"10.1967/s002449913010","DOIUrl":"10.1967/s002449913010","url":null,"abstract":"<p><p>Primary hypertrophic osteoarthropathy (PHO), also known as pachydermoperiostosis, is a rare genetic disorder with autosomal inheritance. We present the case of a 31-year-old male with a disease onset at 12 years of age, initially presenting as digital clubbing of the hands and feet and ankle joint hypertrophy. The clinical phenotype progressed significantly by age 17, with the development of marked facial skin thickening, deepened centripetal skin folds, a corrugated scalp, hypertrophic alae nasi, acne, ptosis, and palmoplantar hyperhidrosis. Anemia was identified at age 19, accompanied by persistent fatigue, followed by the onset of bilateral knee joint pain two years later. Fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) imaging revealed a constellation of findings that can be grouped into three categories: (1) skeletal: cortical thickening and periosteal reaction in the long bones of the lower limbs, along with extensively increased bone marrow density throughout the skeleton; (2) soft tissue: diffuse thickening of the cranial and facial skin, and multiple para-spinal soft tissue foci; and (3) systemic: cardiac findings suggestive of anemia-related adaptation. Genetic analysis confirmed the diagnosis by identifying heterozygous mutations in the SLCO2A1 gene (c.290G>A [p.R97H] and c.1295+1G>A), establishing PHO complicated by anemia.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"132-134"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic clinical indicators in patients with metastatic castration-resistant prostate cancer treated with radium-223 plus enzalutamide: Data from patients in J-RAP-BSI trial.","authors":"Kazuhiro Kitajima, Junpei Kuyama, Takashi Kawahara, Tsuyoshi Suga, Tomoaki Otani, Shigeyasu Sugawara, Yumiko Kono, Yukihisa Tamaki, Ayumi Seko-Nitta, Yoshinobu Ishiwata, Kimiteru Ito, Akira Toriihara, Shiro Watanabe, Makoto Hosono, Shingo Yamamoto, Mitsuhiro Narita, Koichiro Yamakado","doi":"10.1967/s002449913002","DOIUrl":"10.1967/s002449913002","url":null,"abstract":"<p><strong>Objective: </strong>To investigate clinical factors associated with prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases treated with radium-223 dichloride (²²³Ra) and enzalutamide combination therapy.</p><p><strong>Subjects and methods: </strong>This retrospective study included a cohort of 71 mCRPC patients in Japan who underwent combination therapy with ²²³Ra and enzalutamide at 14 hospitals and had pretreatment bone scintigraphy findings available for analysis. Associations of overall survival (OS) with clinicopathological factors, including Eastern Cooperative Oncology Group (ECOG) performance status, hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), prostate-specific antigen (PSA), PSA doubling time, automated bone scan index (aBSI), and previous chemotherapy history, were assessed using the Cox proportional hazards model and log-rank testing.</p><p><strong>Results: </strong>Sixty (84.5%) of the 71 patients enrolled completed six cycles of ²²³Ra. The mean follow-up period was 21.9 months (range, 3.9-62.9 months), during which 35 patients (49.3%) died. Univariate analysis demonstrated that low hemoglobin (<12g/dL, P<0.0001), high PSA (≥20ng/mL, P<0.0001), ALP above the normal range (P=0.0067), and high aBSI (≥2.0%, P=0.0006) were significantly associated with shorter OS. In multivariable analysis, low hemoglobin [hazard ratio (HR) 5.52, 95% confidence interval (CI) 2.32-14.2, P<0.0001] and high PSA (HR 3.06, 95% CI 1.07-9.78, P=0.037) were identified as significant prognostic factors for OS.</p><p><strong>Conclusion: </strong>In patients with mCRPC treated with ²²³Ra and enzalutamide combination therapy, pretreatment hemoglobin and PSA levels may serve as useful surrogate biomarkers for predicting overall survival.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"76-84"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG PET/CT of primary malignant melanoma arising from the Eustachian tube region.","authors":"Qianting Liu, Ting Jiang, Guohua Shen, Yuhao Li","doi":"10.1967/s002449913012","DOIUrl":"10.1967/s002449913012","url":null,"abstract":"<p><p>Primary malignant melanoma arising from the Eustachian tube is extremely rare. Herein, we reported a case of a 50-year-old woman with right-sided aural fullness. On fluorine-18-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) scans, it presented as mild soft tissue thickening of the right nasopharynx with shallowing of the Rosenmüller fossa and avid ¹⁸F-FDG uptake with a maximum standardized uptake value (SUVmax) of 10.59. Postoperative pathology confirmed malignant melanoma of the right torus tubarius.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"137-138"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antoine Henri Becquerel, radioactivity, and the foundations of Nuclear Medicine.","authors":"Andreas Otte","doi":"10.1967/s002449913007","DOIUrl":"10.1967/s002449913007","url":null,"abstract":"<p><p>Henri Becquerel's discovery of natural radioactivity in 1896 marked a turning point in the history of science and laid the foundation for modern nuclear physics and nuclear medicine. This overview reviews Becquerel's life, his scientific career, and the experiments that led to the identification of spontaneous radiation emitted by uranium compounds. It also highlights the subsequent contributions of Marie and Pierre Curie, who expanded the understanding of radioactivity through the discovery of polonium and radium. Furthermore, the article discusses the early therapeutic applications of radium and the lasting impact of Becquerel's work on diagnostic imaging, radionuclide therapy, and radiation oncology. More than 130 years after his discovery, Becquerel's scientific legacy remains fundamental to contemporary medicine and is commemorated by the SI unit of radioactive activity, the becquerel (Bq).</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":" ","pages":"121-124"},"PeriodicalIF":0.8,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}